

Prosigna® Breast Risk of Recurrence Test

PATIENT REPORT

REPORT STATUS: FINAL
PAGE: 1 of 3

PATIENT

Name: Jane Doe
Date of Birth: 01/01/1964
Medical Record #: 8675309

SPECIMEN INFORMATION

Order Date: 01/24/2026
Specimen ID: AB-12345-A
Specimen Collection Date: 01/23/2026
Specimen Received Date: 01/27/2026
Order Number: 98765

ORDERING CLINICIAN

Name: Dr. Jones
Practice: West Coast Oncology
Address: 123 Ocean Beach Way,
Coastaltown, CA 92123

CLINICAL AND PATHOLOGY INFORMATION

SPECIMEN

Surgical Resection

TUMOR SIZE

> 2 cm

LYMPH NODE STATUS

Node-negative

HORMONE RECEPTOR STATUS

ER+ / PR+

MENOPAUSAL STATUS

Postmenopausal

PROSIGNA TEST RESULT

Prosigna Risk of Recurrence (ROR) Score^{1,2}

78

(Score ranges 0-100)

10-Year Probability of Distant Recurrence (DR)^{1,2}

27%

With standard locoregional therapy
and 5 years of endocrine therapy

Predicted Chemotherapy Benefit^{2,3}

Yes

Prosigna ROR score >60

Intrinsic Subtype

**Luminal
B**

Prosigna Test Result Summary

A risk of recurrence (ROR) score of 78 results in a 10-year probability of distant recurrence of 27% and a predicted chemotherapy benefit.

ADDITIONAL INFORMATION

Tumor Size and Lymph Node Status

Physical exam or imaging may be used to initially assess tumor size and lymph node status. Final tumor size and lymph node status should be assessed by pathology for accuracy.

Prosigna Risk of Recurrence (ROR) Score

The Prosigna ROR score is generated from gene expression profiling used to assess intrinsic subtypes and a proliferation score which are then weighted together with tumor size to provide the ROR score. The Prosigna ROR score ranges from 0 through 100 and correlates with the probability of distant recurrence (DR) in the tested population. The percentage shown in the 10-year probability of distant recurrence box above is the modeled probability of distant recurrence at 10 years with 5 years of endocrine therapy for the individual ROR measured.

10-Year Probability of Distant Recurrence

The Prosigna algorithm was used in retrospective analysis of the ABCSG-8 clinical trial which included more than 1400 patients with varying risks of distant recurrence. The retrospectively fitted model related the Prosigna ROR score to 10-year distant recurrence for node-negative patients in the ABCSG-8 study.

Predicted Chemotherapy Benefit

Patients with a Prosigna ROR score of ≤ 60 are predicted to have minimal to no benefit from chemotherapy, whereas those with an ROR > 60 are predicted to benefit from chemotherapy. Chemotherapy benefit prediction is based on the results of the OPTIMA clinical trial.

In the OPTIMA trial, participants were randomized to Prosigna-guided adjuvant therapy or standard chemotherapy followed by endocrine therapy. In the Prosigna-guided arm, chemotherapy was administered only to participants with a Prosigna ROR score > 60; those with an ROR ≤ 60 were treated with endocrine therapy alone (including ovarian suppression in premenopausal women). With a demonstrated non-inferiority margin of 2%, the OPTIMA trial concluded that Prosigna-guided therapy was non-inferior for invasive breast cancer free survival (IBCFs), supporting the use of Prosigna ROR to guide chemotherapy decisions.

Intrinsic Subtype

The intrinsic subtype is based on the PAM50 classifier and determined by the biology of the breast cancer tumor. Classifications are: Luminal A, Luminal B, HER2 enriched, or Basal-like. Concordance with histopathologic subtyping is not established.

Approved By:

E-SIGNED BY NAME, CREDENTIAL ON DATE AT TIME

CLIA ID Veracyte Labs SD# 05D2055897
Lab Director: [Lab Director Name, MD]

A copy of this form shall be as valid as the original. This test was developed and its performance characteristics determined by Veracyte Labs. The laboratory is regulated under CLIA '88 as qualified to perform high complexity clinical testing. This test has not been cleared or approved by the FDA. This test is used for clinical purposes and clinical correlation of its results are recommended. It should not be regarded as investigational or for research.

PROS-004B-0726 ©2026 Veracyte, Inc. The trademarks mentioned herein are the property of Veracyte (for a non-exhaustive list, see www.veracyte.com/trademarks) or their respective owners.



Veracyte Labs SD
6925 Lusk Boulevard, Suite 200
San Diego, CA 92121

Phone
1.888.923.4762
1.650.243.6300

Fax & Email
1.650.763.4192
customer@veracyte.com

FOR ILLUSTRATIVE PURPOSES ONLY

Prosigna® Breast Risk of Recurrence Test

PATIENT REPORT

REPORT STATUS: FINAL
PAGE: 2 of 3

PATIENT

Name: Jane Doe
Date of Birth: 01/01/1964
Medical Record #: 8675309

SPECIMEN INFORMATION

Order Date: 01/24/2026
Specimen ID: AB-12345-A
Specimen Collection Date: 01/23/2026
Specimen Received Date: 01/27/2026
Order Number: 98765

ORDERING CLINICIAN


Name: Dr. Jones
Practice: West Coast Oncology
Address: 123 Ocean Beach Way,
Coastaltown, CA 92123

ADDITIONAL CLINICAL EVIDENCE

Prognosis for node-negative breast cancer patients was determined based on the probability of distant recurrence (DR) for this patient population in the ABCSG-8 validation study. This study analyzed 1,047 node-negative samples using a prospectively defined analysis plan. The data shown are for postmenopausal women with hormone receptor-positive, node-negative, Stage I and II breast cancer that received 5 years of endocrine therapy.⁴

Prediction for node-negative patients was determined based on the OPTIMA phase III prospective randomized clinical trial. This trial analyzed 327 node-negative samples using a prospectively defined analysis plan.³ The OPTIMA trial demonstration of non-inferiority in a high-clinical risk group, along with the established prognostic value of the Prosigna ROR score in lymph node-negative disease, supports applying the OPTIMA findings to node-negative populations when making chemotherapy treatment decisions.

Prosigna Personalized Results Summary^{1,2,3}



TEST DESCRIPTION

The Prosigna Breast Cancer Gene Signature Assay, branded as the Prosigna Breast Risk of Recurrence test, is intended for use in early-stage Hormone Receptor positive (HR+) invasive breast cancer patients for estimating the 10-year distant recurrence-free survival when treated with standard of care locoregional management and adjuvant endocrine therapy, applied with consideration of other clinicopathologic factors. The Prosigna Risk of Recurrence (ROR) score predicts the benefit of chemotherapy and guides treatment decisions in the intended use population.

Whole transcriptome RNA sequencing analysis is utilized for gene expression profiling of the PAM50-based gene set on RNA extracted from formalin-fixed, paraffin-embedded (FFPE) breast tumor tissue; data is collected from over 21,000 genes and over 425,000 probes across the transcriptome for each patient when the test is performed. The test provides Risk of Recurrence (ROR) score, probability of 10-year distant recurrence, predictive chemotherapy benefit, and intrinsic subtype (Luminal A, Luminal B, HER2-Enriched, Basal-like).

Results should be interpreted by a qualified healthcare professional in the context of the patient's clinical and pathological history. Test results are intended to aid clinical decision-making in alignment with professional guidelines alongside other clinicopathological factors. For more information on the Prosigna test visit Veracyte.com.

CLIA ID Veracyte Labs SD# 05D2055897
Lab Director: [Lab Director Name, MD]

A copy of this form shall be as valid as the original. This test was developed and its performance characteristics determined by Veracyte Labs. The laboratory is regulated under CLIA '88 as qualified to perform high complexity clinical testing. This test has not been cleared or approved by the FDA. This test is used for clinical purposes and clinical correlation of its results are recommended. It should not be regarded as investigational or for research.

PROS-004B-0726 ©2026 Veracyte, Inc. The trademarks mentioned herein are the property of Veracyte (for a non-exhaustive list, see www.veracyte.com/trademarks or their respective owners.



Veracyte Labs SD
6925 Lusk Boulevard, Suite 200
San Diego, CA 92121

Phone
1.888.923.4762
1.650.243.6300


Fax & Email
1.650.763.4192
customer care@veracyte.com

FOR ILLUSTRATIVE PURPOSES ONLY


PATIENT	SPECIMEN INFORMATION	ORDERING CLINICIAN
Name: Jane Doe	Order Date: 01/24/2026	Name: Dr. Jones
Date of Birth: 01/01/1964	Specimen ID: AB-12345-A	Practice: West Coast Oncology
Medical Record #: 8675309	Specimen Collection Date: 01/23/2026	Address: 123 Ocean Beach Way,
	Specimen Received Date: 01/27/2026	Coastaltown, CA 92123
	Order Number: 98765	

CLINICAL TRIAL RESULTS

PREDICTIVE EVIDENCE



PROGNOSTIC EVIDENCE



REFERENCES: 1. Wallden B, Storhoff J, Nielsen N, et al. Development and verification of the PAM50-based Prosigna breast cancer gene signature assay. BMC Medical Genomics 2015 Vol. 8 Issue 1, DOI:10.1186/s12920-015-0129-6.

2. Data on file. 3. Stein RC, et al. First results from the OPTIMA phase III randomized non-inferiority trial of test-directed chemotherapy in patients with high clinical risk ER-positive HER2-negative early breast cancer. In: Proceedings from the American Society of Clinical Oncology; May 30, 2026; Chicago IL. Abstract 500. 4. Gnant M, et al., on behalf of the Austrian Breast and Colorectal Cancer Study Group. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. Annals of Oncology 2014; 25(2):339-45.

CLIA ID Veracyte Labs SD# 05D2055897
Lab Director: [Lab Director Name, MD]

A copy of this form shall be as valid as the original. This test was developed and its performance characteristics determined by Veracyte Labs. The laboratory is regulated under CLIA '88 as qualified to perform high complexity clinical testing. This test has not been cleared or approved by the FDA. This test is used for clinical purposes and clinical correlation of its results are recommended. It should not be regarded as investigational or for research.

PROS-004B-0726 ©2026 Veracyte, Inc. The trademarks mentioned herein are the property of Veracyte (for a non-exhaustive list, see www.veracyte.com/trademarks) or their respective owners.